AAPL327.47+5.81 (+1.81%) ▲|ABBV259.24+2.32 (+0.90%) ▲|ABT102.42+1.67 (+1.66%) ▲|ACN144.04+5.30 (+3.82%) ▲|ADBE219.40+7.23 (+3.41%) ▲|AMAT547.41-15.40 (-2.74%) ▼|AMD524.18-15.51 (-2.87%) ▼|AMGN376.75+5.25 (+1.41%) ▲|AMT169.27+4.62 (+2.80%) ▲|AMZN232.83-0.84 (-0.36%) ▼|AVGO382.28-10.19 (-2.60%) ▼|AXP321.64-19.21 (-5.63%) ▼|BA209.29+0.06 (+0.03%) ▲|BAC61.83+0.55 (+0.90%) ▲|BKNG175.37+2.54 (+1.47%) ▲|BLK1,040.77+3.61 (+0.35%) ▲|BMY62.21+0.70 (+1.14%) ▲|BNY159.46-0.66 (-0.41%) ▼|BRK-B492.57+1.72 (+0.35%) ▲|C132.69+0.81 (+0.61%) ▲|CAT896.48+1.94 (+0.22%) ▲|CL90.86+0.78 (+0.86%) ▲|CMCSA22.28+0.36 (+1.64%) ▲|COF200.25+0.29 (+0.14%) ▲|COP120.68+0.48 (+0.40%) ▲|COST929.68+3.62 (+0.39%) ▲|CRM161.23+4.30 (+2.74%) ▲|CSCO112.76-0.01 (0.00%) ▼|CVS107.83+0.94 (+0.88%) ▲|CVX194.68+0.26 (+0.13%) ▲|DE613.86+3.84 (+0.63%) ▲|DHR192.21-0.29 (-0.15%) ▼|DIS94.57+1.74 (+1.87%) ▲|DUK130.10+0.84 (+0.65%) ▲|EMR147.10+2.20 (+1.52%) ▲|FDX316.56+0.94 (+0.30%) ▲|GD386.17+4.38 (+1.15%) ▲|GE356.21+7.21 (+2.06%) ▲|GEV1,020.28-10.91 (-1.06%) ▼|GILD129.86-1.01 (-0.77%) ▼|GM82.69+2.02 (+2.50%) ▲|GOOG322.10+3.76 (+1.18%) ▲|GOOGL322.24+4.55 (+1.43%) ▲|GS1,069.88-4.84 (-0.45%) ▼|HD325.84+1.13 (+0.35%) ▲|HON243.71-2.56 (-1.04%) ▼|IBM211.32+4.67 (+2.26%) ▲|INTC96.19-4.04 (-4.03%) ▼|INTU290.04+8.51 (+3.02%) ▲|ISRG335.65+3.63 (+1.09%) ▲|JNJ261.61+2.34 (+0.90%) ▲|JPM350.56+0.66 (+0.19%) ▲|KO81.40+0.23 (+0.28%) ▲|LIN509.87+3.55 (+0.70%) ▲|LLY1,197.81+11.94 (+1.01%) ▲|LMT580.77+12.18 (+2.14%) ▲|LOW204.11+2.19 (+1.08%) ▲|LRCX311.77-8.01 (-2.50%) ▼|MA534.88+4.59 (+0.87%) ▲|MCD264.06+1.26 (+0.48%) ▲|MDLZ59.99-0.06 (-0.10%) ▼|MDT82.78+0.77 (+0.94%) ▲|META604.36-1.74 (-0.29%) ▼|MMM170.75+1.16 (+0.68%) ▲|MO72.73+0.65 (+0.90%) ▲|MRK130.24-0.24 (-0.18%) ▼|MS214.04-1.14 (-0.53%) ▼|MSFT381.95+0.37 (+0.10%) ▲|MU929.06-61.16 (-6.18%) ▼|NEE88.94-0.85 (-0.95%) ▼|NFLX69.20+0.31 (+0.45%) ▲|NKE41.00+0.01 (+0.02%) ▲|NOW95.93+3.99 (+4.34%) ▲|NVDA207.41-1.35 (-0.65%) ▼|ORCL117.31-2.73 (-2.27%) ▼|PEP134.99+0.04 (+0.03%) ▲|PFE24.55-0.04 (-0.14%) ▼|PG147.08+1.20 (+0.82%) ▲|PLTR122.85-0.52 (-0.42%) ▼|PM193.77+2.65 (+1.39%) ▲|QCOM167.40-3.71 (-2.17%) ▼|RTX211.72+2.56 (+1.22%) ▲|SBUX104.47+1.26 (+1.22%) ▲|SCHW101.77+0.16 (+0.15%) ▲|SO97.50+0.90 (+0.93%) ▲|SPG227.65+2.45 (+1.09%) ▲|T23.61+0.65 (+2.83%) ▲|TMO562.62-9.70 (-1.69%) ▼|TMUS177.36+6.94 (+4.07%) ▲|TSLA315.64-4.05 (-1.27%) ▼|TXN279.89-5.10 (-1.79%) ▼|UBER68.75-0.17 (-0.24%) ▼|UNH423.17-0.39 (-0.09%) ▼|UNP303.11-1.22 (-0.40%) ▼|UPS114.05-0.05 (-0.04%) ▼|USB63.65+0.32 (+0.51%) ▲|V353.23+1.63 (+0.46%) ▲|VZ45.06+1.24 (+2.82%) ▲|WFC86.24+0.05 (+0.06%) ▲|WMT108.88+0.48 (+0.44%) ▲|XOM157.22+0.33 (+0.21%) ▲|AAPL327.47+5.81 (+1.81%) ▲|ABBV259.24+2.32 (+0.90%) ▲|ABT102.42+1.67 (+1.66%) ▲|ACN144.04+5.30 (+3.82%) ▲|ADBE219.40+7.23 (+3.41%) ▲|AMAT547.41-15.40 (-2.74%) ▼|AMD524.18-15.51 (-2.87%) ▼|AMGN376.75+5.25 (+1.41%) ▲|AMT169.27+4.62 (+2.80%) ▲|AMZN232.83-0.84 (-0.36%) ▼|AVGO382.28-10.19 (-2.60%) ▼|AXP321.64-19.21 (-5.63%) ▼|BA209.29+0.06 (+0.03%) ▲|BAC61.83+0.55 (+0.90%) ▲|BKNG175.37+2.54 (+1.47%) ▲|BLK1,040.77+3.61 (+0.35%) ▲|BMY62.21+0.70 (+1.14%) ▲|BNY159.46-0.66 (-0.41%) ▼|BRK-B492.57+1.72 (+0.35%) ▲|C132.69+0.81 (+0.61%) ▲|CAT896.48+1.94 (+0.22%) ▲|CL90.86+0.78 (+0.86%) ▲|CMCSA22.28+0.36 (+1.64%) ▲|COF200.25+0.29 (+0.14%) ▲|COP120.68+0.48 (+0.40%) ▲|COST929.68+3.62 (+0.39%) ▲|CRM161.23+4.30 (+2.74%) ▲|CSCO112.76-0.01 (0.00%) ▼|CVS107.83+0.94 (+0.88%) ▲|CVX194.68+0.26 (+0.13%) ▲|DE613.86+3.84 (+0.63%) ▲|DHR192.21-0.29 (-0.15%) ▼|DIS94.57+1.74 (+1.87%) ▲|DUK130.10+0.84 (+0.65%) ▲|EMR147.10+2.20 (+1.52%) ▲|FDX316.56+0.94 (+0.30%) ▲|GD386.17+4.38 (+1.15%) ▲|GE356.21+7.21 (+2.06%) ▲|GEV1,020.28-10.91 (-1.06%) ▼|GILD129.86-1.01 (-0.77%) ▼|GM82.69+2.02 (+2.50%) ▲|GOOG322.10+3.76 (+1.18%) ▲|GOOGL322.24+4.55 (+1.43%) ▲|GS1,069.88-4.84 (-0.45%) ▼|HD325.84+1.13 (+0.35%) ▲|HON243.71-2.56 (-1.04%) ▼|IBM211.32+4.67 (+2.26%) ▲|INTC96.19-4.04 (-4.03%) ▼|INTU290.04+8.51 (+3.02%) ▲|ISRG335.65+3.63 (+1.09%) ▲|JNJ261.61+2.34 (+0.90%) ▲|JPM350.56+0.66 (+0.19%) ▲|KO81.40+0.23 (+0.28%) ▲|LIN509.87+3.55 (+0.70%) ▲|LLY1,197.81+11.94 (+1.01%) ▲|LMT580.77+12.18 (+2.14%) ▲|LOW204.11+2.19 (+1.08%) ▲|LRCX311.77-8.01 (-2.50%) ▼|MA534.88+4.59 (+0.87%) ▲|MCD264.06+1.26 (+0.48%) ▲|MDLZ59.99-0.06 (-0.10%) ▼|MDT82.78+0.77 (+0.94%) ▲|META604.36-1.74 (-0.29%) ▼|MMM170.75+1.16 (+0.68%) ▲|MO72.73+0.65 (+0.90%) ▲|MRK130.24-0.24 (-0.18%) ▼|MS214.04-1.14 (-0.53%) ▼|MSFT381.95+0.37 (+0.10%) ▲|MU929.06-61.16 (-6.18%) ▼|NEE88.94-0.85 (-0.95%) ▼|NFLX69.20+0.31 (+0.45%) ▲|NKE41.00+0.01 (+0.02%) ▲|NOW95.93+3.99 (+4.34%) ▲|NVDA207.41-1.35 (-0.65%) ▼|ORCL117.31-2.73 (-2.27%) ▼|PEP134.99+0.04 (+0.03%) ▲|PFE24.55-0.04 (-0.14%) ▼|PG147.08+1.20 (+0.82%) ▲|PLTR122.85-0.52 (-0.42%) ▼|PM193.77+2.65 (+1.39%) ▲|QCOM167.40-3.71 (-2.17%) ▼|RTX211.72+2.56 (+1.22%) ▲|SBUX104.47+1.26 (+1.22%) ▲|SCHW101.77+0.16 (+0.15%) ▲|SO97.50+0.90 (+0.93%) ▲|SPG227.65+2.45 (+1.09%) ▲|T23.61+0.65 (+2.83%) ▲|TMO562.62-9.70 (-1.69%) ▼|TMUS177.36+6.94 (+4.07%) ▲|TSLA315.64-4.05 (-1.27%) ▼|TXN279.89-5.10 (-1.79%) ▼|UBER68.75-0.17 (-0.24%) ▼|UNH423.17-0.39 (-0.09%) ▼|UNP303.11-1.22 (-0.40%) ▼|UPS114.05-0.05 (-0.04%) ▼|USB63.65+0.32 (+0.51%) ▲|V353.23+1.63 (+0.46%) ▲|VZ45.06+1.24 (+2.82%) ▲|WFC86.24+0.05 (+0.06%) ▲|WMT108.88+0.48 (+0.44%) ▲|XOM157.22+0.33 (+0.21%) ▲|
25.9 C
New York
Friday, July 24, 2026

Tag: liver failure

newssourceFORcompanyinformationcontent1releasesmarket

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,...

Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development

Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

Gujarat becomes the New Hub in Organ Transplantation

Zydus Hospitals Ahmedabad and Vadodara reach new heights in advanced transplant care AHMEDABAD, India, June 4, 2026 /PRNewswire/ -- Organ transplantation in India has come a...

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) and certain of its officers.

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH 
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty...

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 10, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™...

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 11, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™...

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 11, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™...

Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta and Petco and Encourages Investors to Contact the...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta (SRPT) or PetCo (WOOF) To Contact Him Directly To Discuss Their Options

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLiver failure

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers